BCM
CLMT icon

BlueCrest Capital Management’s Calumet Specialty Products CLMT Stock Holding History

BlueCrest Capital Management’s Portfolio CLMT Stock Details CLMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10,000
Closed -$11K – 252
2020
Q1 		$11K Buy
+10,000
New +$33.8K ﹤0.01% 210

Other funds holding CLMT

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WDOM
Wasserstein Debt Opportunities Management New York $264M AUM 188.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Adams Asset Advisors Dallas, Texas $984M AUM 41.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlueCrest Capital Management's CLMT Position: Q2 2026 in Review

BlueCrest Capital Management increased its Calumet Specialty Products (CLMT) stake by 33% in Q2 2026, buying an estimated $672K and bringing the position to 80,000 shares worth $2.88M. The position accounts for 0.09% of the portfolio, ranked #137.

BlueCrest Capital Management first reported a position in CLMT in Q3 2024 and has held it in 8 quarters since. 188 funds tracked by Wall St. Rank hold CLMT as of Q2 2026.

  • BlueCrest Capital Management held 80,000 shares of Calumet Specialty Products worth $2.88M as of Q2 2026.
  • BlueCrest Capital Management bought 20,000 Calumet Specialty Products shares in Q2 2026, an estimated $672K.
  • Calumet Specialty Products made up 0.09% of BlueCrest Capital Management's portfolio in Q2 2026, its #137 holding.
  • BlueCrest Capital Management first reported a position in Calumet Specialty Products in Q3 2024 and has held it in 8 quarters since.
  • 188 funds tracked by Wall St. Rank held Calumet Specialty Products as of Q2 2026.

Based on BlueCrest Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.